| Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announces that the June 2011 FDA approval of LAVIV™ (azficel-T) for the improvement of the appearance of "smile line" wrinkles was named the #3 top story of 2011 in cell and gene therapy and regenerative medicine at The 2012 Cell & Gene Therapy Forum in Washington, D.C. The award was voted by T...continued FCSC |
Monday, January 30, 2012
Fibrocell Science, Inc. Announces Recognition for LAVIV(tm) (azficel-T) at The 2012 Cell & Gene Therapy Forum, Washington, D.C.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment